Colossal Biosciences unveiled GenoMorph, an AI-driven platform designed to speed up genetic analysis and editing in de-extinction projects, addressing key challenges of limited ancient DNA availability.
- GenoMorph uses AI to identify precise genetic edits from few genomes.
- Platform supports gene editing experiments through rapid developmental testing.
- Investor Peter Diamandis launches fund to back startups using GenoMorph.
What happened
Colossal Biosciences introduced GenoMorph, an AI platform that harnesses 3D morphological data, comparative genomics, and developmental biology to overcome the limitations posed by scarce DNA samples in de-extinction efforts. Unlike the more plentiful mammoth genome, the dodo’s genomic data is limited to a single complete sequence, necessitating advanced AI techniques to identify key genetic targets.
The company combined developmental data from birds closely related to the dodo, such as chickens and pigeons, with genetic and 3D skull measurements from over 70 bird species to train GenoMorph. This platform has already identified around 2,300 promising DNA editing targets involved in the dodo’s distinctive craniofacial features, substantially narrowing the field for laboratory testing.
Why it matters
By enabling more precise identification of gene-editing targets with limited genomic data, GenoMorph significantly advances the practicality and accuracy of de-extinction science. Traditionally requiring the comparison of many genomes, this approach minimizes guesswork and accelerates the experimental cycle for recreating extinct species’ physical traits.
Furthermore, Colossal has developed complementary methods such as lipid nanoparticle delivery of gene-editing tools directly into developing bird embryos, allowing faster validation of gene modifications without lengthy breeding cycles. This integrated strategy increases efficiency and safety by enabling controlled testing before any full organism development.
What to watch next
Colossal plans to validate GenoMorph’s predicted gene edits in laboratory settings, testing how genetic changes impact trait development. The company’s progress with its Nicobar pigeon colony—dodo’s closest living relative—and creation of cells that can form eggs and sperm are key components in this phase.
Investment momentum is building as well, with XPRIZE founder Peter Diamandis launching a new fund to support startups utilizing GenoMorph technology, signaling broader interest and potential collaboration within the biotech and conservation sectors. Observers will be keen to see which projects adopt this AI-driven approach and how it shapes the future of synthetic biology and species restoration.